在扩散大B细胞淋巴瘤中对抗CD19CAR-T细胞治疗的耐药性的功能驱动因素
Austin D Newsam1,2,3, Caroline A Coughlin1,2,3, Asaad Trabolsi3,4
1Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL, USA.
Leukemia & lymphoma
|November 7, 2023
概括
针对CD19 (CAR-19) 的化学抗原受体T细胞疗法对大B细胞淋巴瘤 (LBCL) 有希望,但耐药性仍然是一个挑战. 本综述强调了耐药性的生物标志物,并提出了未来验证的实验框架.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 针对CD19 (CAR-19) 的化学抗原受体T细胞疗法为复发或耐药的大B细胞淋巴瘤 (LBCL) 提供了持久的缓解.
- 在接受CAR-19治疗的LBCL患者中,超过一半的患者没有反应或最终进展,这表明存在显著的抗药性机制.
- 目前关于CAR-19耐药性的研究主要集中在宿主因素,CAR-T产品特征和瘤微环境 (TME) 改变上,对瘤内在基因组因素的研究有限.
研究的目的:
- 审查现有的关于与LBCL中CAR-19治疗耐药性相关的生物标志物的文献.
- 突出瘤基因组改变在CAR-19耐药性中的未被研究的作用.
- 提出一个用于识别和验证CAR-19耐药性生物标志物的实验框架.
主要方法:
- 对调查LBCL中CAR-19耐药机制的研究进行了全面的文献综述.
- 分析与患者结果相关的因素,包括临床参数,CAR-T产品成分,TME变化和基因组复杂性.
- 确定当前研究中的差距,特别是关于功能性耐药性实验室研究的差距.
主要成果:
- 在宿主,CAR-T产品和TME领域中确定了耐药性的关键生物标志物.
- 瘤细胞内的基因组变化相对较少研究,但可能是抗性的重要媒介.
- 缺乏功能性实验室研究阻碍了对候选耐药性改变的确认.
结论:
- 了解耐药机制对于改善LBCL的CAR-19治疗疗效至关重要.
- 瘤内在的基因组变化需要进一步调查,因为它们是抵抗力的关键驱动因素.
- 需要一个综合实验方法,结合生物标志物识别和功能验证,以推进CAR-19治疗.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
936
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K